Sep 18, 2022 · The goal of the trial was to evaluate the safety and efficacy of pulmonary artery denervation (PADN) among patients with Group I pulmonary arterial hypertension (PAH) who were not on PAH-specific drugs.

treatment of transthoracic pulmonary artery (PA) denervation (PADN). Pulmonary arte-rial hypertension (PAH) is associated with increased sympathetic nervous system and renin-angiotensin-aldosterone system activa-tion. The central nervous system provides au-tonomic output to the PA, heart, and kidney. Sympathetic tone activation leads increased

Oct 2, 2022 · Pulmonary artery denervation (PADN) is emerging as a potential novel therapy for this condition. The basis of pursuing a sympathetic denervation strategy has its origins in a body of experimental translation work that has demonstrated that denervation can reduce sympathetic nerve activity in various animal models.

Sep 16, 2022 · Treatment with pulmonary artery denervation (PADN) plus a phosphodiesterase-5 inhibitor (PDE-5i) was safe in patients with stable pulmonary arterial hypertension (PAH), based on findings from the PADN-CFDA study presented Sept. 18 during TCT 2022 and simultaneously published in JACC: Cardiovascular Interventions. Researchers also noted improved ...

Mar 21, 2023 · BOSTON, MA—There are more encouraging signs that pulmonary artery denervation may one day bring relief to patients who have pulmonary arterial hypertension (PAH) due to left heart disease.

Sep 5, 2019 · The purpose of this review is to illustrate localization of pulmonary arterial sympathetic nerves, the key steps of pulmonary artery denervation (PADN) procedure, and to highlight clinical outcomes. Sympathetic nerves mostly occurred in the posterior region of the bifurcation and pulmonary trunk.

Aug 18, 2020 · Pulmonary artery denervation (PADN) is an exciting new adjunctive therapy for PAH. This trial, in conjunction with the recently published TROPHY1, suggests a role for PADN in PAH patients moving forward.

Jun 1, 2020 · Pulmonary artery denervation was found to be safe and to improve the health of people with pulmonary arterial hypertension (PAH), according to results of an early clinical trial.

In the absence of drugs modulating sympathetic nervous system activation, a viable alternative consists of interventional options that block the sympathetic nerve supply to pulmonary arteries. 1 One technique showing promise in emerging studies is pulmonary artery denervation (PADN), which has been found to reduce the sympathetic activity of ...

BOSTON – September 18, 2022 – A new sham-controlled clinical evaluation of pulmonary artery denervation (PADN) for patients with pulmonary arterial hypertension (PAH) found that in addition to increasing exercise capacity, PADN improved hemodynamics and clinical outcomes during six-month follow-up.